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Abstract
Although medulloblastoma is the most common pediatric malignant brain tumor, its molecular underpinnings are
largely unknown. We have identified rare, recurrent homozygous deletions of Kruppel-like Factor 4 (KLF4) in medullo-
blastomausing high-resolution single nucleotide polymorphismarrays, digital karyotyping, andgenomic real-timepoly-
merase chain reaction (PCR). Furthermore, we show that there is loss of physiological KLF4 expression in more than
40% of primary medulloblastomas both at the RNA and protein levels. Medulloblastoma cell lines drastically increase
the expressionofKLF4 in response to the demethylating agent 5-azacytidine anddemonstrate densemethylationof the
promoter CpG island by bisulfite sequencing. Methylation-specific PCR targeting the KLF4 promoter demonstrates
CpG methylation in approximately 16% of primary medulloblastomas. Reexpression of KLF4 in the D283 medullo-
blastomacell line results in significant growthsuppressionboth in vitroand in vivo.Weconclude thatKLF4 is inactivated
by either genetic or epigeneticmechanisms in a large subset ofmedulloblastomasand that it likely functions as a tumor
suppressor gene in the pathogenesis of medulloblastoma.
Neoplasia (2010) 12, 20–27
Introduction
Medulloblastoma is the most common malignant pediatric brain
tumor. Current therapies including surgery, craniospinal radiotherapy,
and chemotherapy result in modest 5-year survivals (60%-70%) and
predispose to many long-term complications such as cognitive im-
pairment, focal neurologic deficits, and secondary malignancies [1].
Development of novel targeted therapies for medulloblastoma has been
hindered by modest levels of genetic and epigenetic data concerning its
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Figure 1. (A) Copy number analysis of 79 primary human medulloblastomas and 10 medulloblastoma cell lines profiled on the Affymetrix
100K SNP genotyping platform demonstrates that one primary tumor (sample MB-14) carries a 2.05-Mb homozygous deletion mapping to
chromosome 9q31.2-q31.3 (highlighted in yellow box). Output is inferred log2 copy number data from dChip, with regions of gain shown in
red and regions of loss shown in blue. Monosomy on chromosome 9q is observed in 8 (∼10.1%) of 79 samples. (B) UCSC output (NCBI
Build 35; hg17) showing chromosome 9q inferred copy number data for HSC-MB-14, highlighting the region of homozygous deletion iden-
tified by SNP array. The homozygous deletion encompasses eight RefSeq genes (highlighted in red ellipsoid): ZNF462, RAD23B, KLF4,
ACTL7B, ACTL7A, IKBKAP, C9orf6, and CTNNAL1. (C) Homozygous deletion encompassing the KLF4 locus as detected by digital karyotyping
in 1 of 18 tumor samples. This region of homozygous deletion overlaps with the same region described in (B). Horizontal white line indicates
a diploid copy number. Arrow points to the KLF4 locus. (D) Real-time genomic PCR confirming homozygous deletion of KLF4 in the two
medulloblastoma samples described in (A, B) and (C). Template from normal brain and HSC-MB-7 were included as negative controls. An
unrelated genomic locus on chromosome 1p33 (Chr1p33) was also included.
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pathogenesis and, therefore, a paucity of targets for the development of
novel therapies [2–10]. Owing to the relatively small number of chil-
dren with medulloblastoma compared with adults with epithelial ma-
lignancies, it would be advantageous to identify medulloblastoma
targets that are shared with the more common adult epithelial malig-
nancies because compounds against these targets are more likely to be
developed by the pharmaceutical industry. We demonstrate that the
known tumor suppressor gene (TSG) KLF4 is inactivated in a substan-
tial subset of medulloblastomas through either genetic or epigenetic
mechanisms. KLF4 is a TSG that has previously been reported as epi-
genetically silenced in colonic, gastric, and pancreatic carcinoma, as well
as in hematopoietic malignancies, and which is mutated in colon cancer
[11–13]. KLF4 has also been reported to act as an oncogene in other
histologic types of cancer [14–16]. Haploinsufficiency for Klf4 has been
demonstrated to promote tumorigenesis in mouse models of colonic
cancer [17]. Forced reexpression of KLF4 in a number of cancer cell
lines diminishes tumorigenicity both in vitro and in vivo, supporting
its role as a bona fide TSG [11,12].
In the current study, we demonstrate that KLF4 is either deleted or
silenced by promoter CpG island methylation in a large subset of
medulloblastomas. Whereas KLF4 is highly expressed in the normal
human adult and fetal cerebella, there is no significant expression of
KLF4 in approximately 46% of human medulloblastomas. Forced
reexpression of KLF4 in the D283 medulloblastoma cell line results
in decreased growth both in vitro and in vivo. Our results support
the hypothesis that KLF4 functions as a TSG in the pathogenesis
of medulloblastoma.
Materials and Methods
Cell Lines, Normal Cerebella, and Medulloblastoma Samples
ONS76 was obtained from the Institute for Fermentation (Osaka,
Japan). UW228 and UW426 were obtained from J. Silber (University
of Washington, Seattle, WA). D425, D458, and D384 were obtained
from Darrell Bigner (Duke University, Durham, NC). MHH-MED1
and MED8a were obtained from Richard Gilbertson (St. Jude Chil-
dren’s Research Hospital, Memphis, TN). RES261 was obtained from
Michael Bobola (University of Washington, Seattle, WA). Other cell
lines were purchased from the American Type Culture Collection
(Rockland, MD). Medulloblastoma samples were collected after in-
stitutional review board approval, and DNA and RNA were isolated
as published [18]. Samples of normal adult and fetal cerebella were
purchased from Biochain (Hayward, CA).
5-Azacytidine Treatment and Quantitative Reverse
Transcription–Polymerase Chain Reaction
Cell lines were plated at 20% to 30% confluence in Dulbecco’s
modified Eagle medium with 10% fetal calf serum. Twenty-four
hours later, the medium was replaced with fresh medium containing
5 mM 5-azacytidine (5-Aza; Sigma-Aldrich, Inc, St Louis, MO) or an
equal volume of vehicle (PBS). Medium and drug or vehicle was re-
placed every 24 hours during a 72-hour period.
Copy Number Determination
Genotyping on the Affymetrix 100K single nucleotide polymorphism
(SNP) arrays was performed as published [18]. Expression profiling of
medulloblastoma specimens was performed on the Affymetrix Exon
Array platform as published [19]. Digital karyotyping was performed as
published [20].
Bisulfite Sequencing and Methylation-Specific PCR
Genomic DNAwas treated with MethylEasy DNA Bisulphite Mod-
ification Kit (Human Genetic Signatures, North Ryde, Australia). For
bisulfate sequencing, modified DNA was amplified using primers
BSQ1: forward 5′-ttggaaaattattgattataaattaagg-3′ and reverse 5′-
cttccctaaaaaataaccatatacc-3′; and BSQ2: forward 5′-gttygagtttttat-
tattttttagtg-3′ and reverse 5′-attttactctcatcttcttaacaaaca-3′. Amplified
products were cloned using the Topo-TA cloning system (Invitrogen,
Carlsbad, CA) and Sanger sequenced at The Center for Applied Geno-
mics (Toronto, Canada). Methylation-specific PCR (MSP) was carried
out on bisulfate-treated DNA from 44 primary medulloblastomas. Un-
methylated KLF4 forward 5′-gttaatttatgtttagaaagtgatattg-3′ and reverse
5′-tacacaccaaacccaccacaaac-3′. Methylated KLF4 forward 5′-gttaatt-
tatgtttagaaagtgatattg-3′ and reverse 5′-tacacaccaaacccaccacaaac-3′.
CPGenome universally methylated DNA (Chemicon, Temecula, CA)
was used as a positive control.
Cell Proliferation Assay
MTS assay was performed as published [21].
Orthotopic Intracerebellar Xenografts
D283 medulloblastoma cells transfected with pcDNA-KLF4 or
vector control were injected at a final concentration of 50,000 cells
per milliliter into the cerebellum of Nu/Nu mice (aged 5-6 weeks,
Charles River, Canada) as published [22]. Mice were killed at the
time of development of a symptomatic intracranial mass such as a
domed skull, incoordination, lethargy, or significant weight loss.
Figure 2. (A) Expression status of genes homozygously deleted on chromosome 9q31.2-q31.3 in normal cerebellum (n = 10) and primary
medulloblastomas (n= 103) as determined by Affymetrix exon arrays. Box plots representing normalized log2-transformed expression array
data for the eight RefSeq genes are shown. Of the eight candidate genes, KLF4 exhibits the greatest reduction in transcript expression level
in medulloblastoma compared to normal controls. P values determined using t test statistics are shown. NS = not significant. y-axis =
normalized signal intensity from exon array expression data. (B) Quantitative RT-PCR analysis of KLF4 in primary medulloblastomas (n =
40) demonstrates at least two-fold down-regulation of KLF4 expression compared with normal cerebellum in approximately 88% (35/40) of
medulloblastomas. Samples with at least two-fold down-regulation are highlighted in blue. KLF4 expression values were determined by
normalization to β-actin and calibration to normal adult cerebellum. (C) Staining of a human medulloblastoma tissue microarray with anti-
bodies to KLF4 shows that KLF4 staining is absent in 32 (∼46%) of 69 cases. Representative cases are shown. (D) Right panel. Quantitative
RT-PCR demonstrates robust reexpression of the KLF4 transcript in seven of nine medulloblastoma cell lines after treatment with the
DNA methylation inhibitor 5-Aza (highlighted red) compared to mock-treated cells (highlighted black). Left panel. Western blot analysis
demonstrating reexpression of KLF4 in the medulloblastoma cell lines D283 and DAOY after treatment with 5-Aza.
22 KLF4 is Inactivated in Medulloblastoma Nakahara et al. Neoplasia Vol. 12, No. 1, 2010
Neoplasia Vol. 12, No. 1, 2010 KLF4 is Inactivated in Medulloblastoma Nakahara et al. 23
Figure 3. (A) Schematic representation of the CpG island found in the promoter region of the KLF4 genomic locus. Exons located within the
CpG island are illustrated. Numbers indicate position relative to the transcriptional start site. The regions interrogated by bisulfite sequenc-
ing and MSP below are marked in red and blue, respectively. (B) Bisulfite-converted DNA from normal adult and fetal cerebellum were
amplified at the KLF4 promoter, and fragments were TA-cloned and sequenced. CpG sites are represented as boxes, with shaded regions
indicating methylation and unshaded regions indicating no methylation. The KLF4 promoter is hypomethylated in the normal adult and fetal
cerebellum, with a minimal number of CpGs showing methylation. (C) Bisulfite sequencing of the KLF4 promoter in medulloblastoma cell
lines shows densemethylation in ONS76, D283, Daoy, Med8a, Med1, RES262, and UW228. Notably, there is only sparse methylation in the
D425 cell line, which also did not show an increase in KLF4 expression after treatment with 5-Aza. (D) MSP for a region of the KLF4 promoter.
A total of 5 medulloblastoma cell lines and 44 primary medulloblastomas were included in the analysis. A methylated band was amplified
in 7 (∼16%) of 44 primary samples. Universally methylated DNA and normal adult and fetal cerebellar samples were included as controls
for the methylated (M) and unmethylated (U) primers, respectively.
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Human Medulloblastoma Tissue Microarray
Human medulloblastoma TMA was stained with anti-KLF4 anti-
bodies (Santa Cruz Biotechnology, Santa Cruz, CA) and interpreted
as previously published [18].
Results
Recurrent Homozygous Deletion of KLF4 in Medulloblastoma
We used high-resolution SNP genotyping arrays to determine copy
number aberrations in the genome of 201 primary medulloblastomas
[18]. Loss of heterozygosity on chromosome 9q was observed in ap-
proximately 14% (11/79) of tumors, and one case harbored a region
of homozygous deletion at 9q31.2-q31.3 that encompasses eight
known genes (Figure 1A). This region of homozygous loss contains
eight RefSeq genes: ZNF462, RAD23B, KLF4, ACTL7B, ACTL7A,
IKBKAP, C9orf6, and CTNNAL1 (Figure 1B). In a separate study, on
a nonoverlapping group of medulloblastomas, copy number aberrations
in a series of 18 medulloblastomas were determined using digital karyo-
typing technology, and a second, overlapping but not identical homo-
zygous deletion at 9q31.2 was identified (Figure 1C ). Both of these
homozygous deletions were validated using quantitative genomic PCR
(Figure 1D). Recurrent homozygous deletions in primary tumors of a
given tumor type are very significant, and indeedmany of the best known
TSGs have been discovered through the characterization of rare homo-
zygous deletions [23–25].
Loss of Expression of KLF4 in Medulloblastoma
To gain insight into which gene(s) was acting as a “driver(s)” in the
region of homozygous deletion on chromosome 9q31, we compared
the expression pattern of the eight candidates in a cohort of 103medullo-
blastomas compared with normal cerebellum (n = 10) using Affymetrix
exon arrays [19]. Of these eight genes, only KLF4 and CTNNAL1
showed a significant decrease in expression in tumors compared with
normal tissue control using exon array expression data (Figure 2A).
KLF4 is a known TSG that is epigenetically silenced in colon cancer,
gastric cancer, and leukemia [11–13,26]. Recurrent homozygous dele-
tion and down-regulation of KLF4 in primary medulloblastoma suggests
that it may function as a TSG in the pathogenesis of medulloblastoma.
To confirm the expression array data, we used quantitative reverse
transcription–polymerase chain reaction (RT-PCR) to compare the ex-
pression level of KLF4 in primary medulloblastomas to both adult and
fetal human cerebellum. KLF4 expression was dramatically reduced in
medulloblastomas compared with normal controls, with 35 (∼88%) of
40 cases exhibiting at least a two-fold reduction in transcript abundance
compared with normal adult and fetal cerebellum when compared by
quantitative RT-PCR (Figure 2B). To further investigate the status of
KLF4 in primary medulloblastomas, we stained a medulloblastoma
tissue microarray containing 69 primary cases with anti-KLF4 anti-
bodies. KLF4 protein was not detected in approximately 46% (32/69)
of tumors (Figure 2C ). Lack of expression of KLF4 did not correlate
with prognosis on our MB tissue microarray. Epigenetic silencing of
Figure 4. (A) Stable reexpression of KLF4, but not controls, results in growth suppression of the D283medulloblastoma cell line as assessed
by MTS assay. (B) D283 cells stably reexpressing KLF4 exhibit reduced colony-forming capacity compared to empty vector control cells as
assessed by soft agar assay. (C) Quantification of colony formation data obtained for D283-empty vector and D283-KLF4 stable cell lines
grown in soft agar. Values represent the mean colony number for three independent experiments performed in triplicate for each cell line.
P value was calculated using t test statistics.
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TSGs through methylation of CpG dinucleotides within their promoter
regions has become increasingly apparent in human cancers, including
medulloblastomas [22,27,28]. To determine whether KLF4 deregula-
tion may be attributable to promoter hypermethylation, we treated
nine medulloblastoma cell lines with 5-Aza to reverse CpG methylation
and subsequently checked for reexpression of KLF4 transcript. Indeed,
treatment with 5-Aza resulted in robust reexpression of KLF4 in seven
(∼78%) of nine medulloblastoma cell lines (Figure 2D, left panel ). In
addition, increased expression of the KLF4 protein is observed in the
D283 and Daoy cell lines by immunoblot analysis after 5-Aza treatment
(Figure 2D, right panel ).
Methylation of the KLF4 Promoter in Medulloblastoma
To elucidate whether the robust reexpression of KLF4we observed in
cell lines treated with 5-Aza was a direct result of CpG island hyper-
methylation, we next bisulfite-sequenced the KLF4 promoter region
using genomic DNA templates isolated from normal human adult
and fetal cerebella and eight medulloblastoma cell lines (Figure 3A).
Profiling a region containing 25 CpG sites upstream of the KLF4 tran-
scriptional start site demonstrated that there is only extremely rare
CpG methylation in the normal human adult and fetal cerebellum
(Figure 3B). In contrast, dense methylation of the KLF4 promoter is
observed in seven of eight medulloblastoma cell lines (Figure 3C ).
Interestingly, of the cell lines profiled, only one, the D425 cell line,
did not show significant CpG methylation in the KLF4 promoter
(Figure 3C), which is significant in light of the fact that KLF4 expres-
sion remained unchanged inD425 cells treated with 5-Aza (Figure 2D).
We performed MSP and demonstrated KLF4 promoter methylation in
approximately 16% (7/44) of primary medulloblastomas (Figure 3D).
We conclude that KLF4 promoter CpG hypermethylation is found in
a subset of medulloblastomas, but not in normal cerebellum, and that
this methylation is likely associated with transcriptional silencing. Ad-
ditional medulloblastomas that fail to express KLF4, but for which
we could not demonstrate promoter methylation using methylation-
sensitive PCR could carry other genetic or epigenetic events, including
transcriptional repression to account for the lack of expression of KLF4.
KLF4 Functions as a TSG In Vitro and In Vivo
To functionally evaluate the role of KLF4 as a TSG in medullo-
blastoma, we stably reexpressed KLF4 in the D283 medulloblastoma
cell line in which its expression is silenced. Stable reexpression of
KLF4 in D283 cells resulted in nearly complete growth cessation com-
pared with either parental or empty vector control cells by MTS assay
(Figure 4A). This is very consistent with reexpression of a TSG in a
malignant cell population. A similar pronounced effect was observed
in the soft agar assay, with D283 cells stably expressing KLF4 exhibiting
a significant reduction in colony-forming capacity compared to con-
trols (Figure 4, B and C ; t test, P = 3.68e − 08). Finally, intracerebellar
xenografting of D283 medulloblastoma cells expressing KLF4 led to
a clinically and statistically significantly increased survival compared
with empty vector controls (Figure 5; log-rank test, P = .0052). That
reexpression of just one gene—KLF4—can increase the survival of
mice bearing medulloblastoma xenografts is quite striking, in that can-
cer genome resequencing projects are predicting that each tumor carries
at least 10 and perhaps hundreds of driver mutations [29]. Our data
demonstrate that KLF4 activity is abrogated by either genetic or epi-
genetic events in a significant subset of primary medulloblastomas
and that restoration of KLF4 function in medulloblastoma results in
decreased growth, decreased colony formation, and increased survival
in an in vivo xenograft model. These data support our hypothesis that
KLF4 functions as a TSG in medulloblastoma.
Discussion
KLF4 has been shown to interact with a number of pathways with well-
documented links to medulloblastoma biology. KLF4 transactivates
expression of the cell cycle arrest factor p27Kip1, which plays a critical
role in the differentiation of granule neuron progenitor cells, one of
the putative cells of origin for a subset of medulloblastomas, and a
putative medulloblastoma TSG [30,31]. Klf4 has also been shown to
bind to the promoter of Ccnd2 (encoding cyclin D2) and diminish its
expression [32]. This is critical in that Ccnd2 knockout mice exhibit
cerebellar hypoplasia, and CCND2 is frequently overexpressed in
medulloblastoma [33,34]. Notch signaling has been shown to repress
KLF4, which is pertinent in that Notch signaling plays an important
role in the developing cerebellum, and NOTCH2 is amplified in a sub-
set of medulloblastomas [35–37]. KLF4 has also been shown to repress
the Wnt signaling pathway, which also has been shown to be hyper-
activated in a subset of medulloblastomas [17,38,39]. As several of
these signaling pathways are active in distinct subgroups of medullo-
blastoma [39], and as KLF4 has been shown to undergo loss of func-
tion in a variety of other cancer types, we suspect that KLF4 function
in lost in more than one subgroup of medulloblastoma. To formally
Figure 5. Kaplan-Meier survival curve of nudemice with intracerebellar xenografts of D283 reexpressing KLF4 (n=10) or vector control (n=
10). There is a statistically significant increase in survival of mice injected with the KLF4 expressing xenografts (log-rank test, P = .0052).
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determine if this is true, the hypothesis will need to be tested on a clini-
cally well-annotated series of medulloblastoma for which both high-
quality genomic DNA and paraffin sections are available. Because
KLF4 is targeted in a number of other neoplasms, we suspect that com-
pounds targeting this event will be developed in the future, at which
time they should be tested in medulloblastoma model systems as a
prelude to future clinical trials in children with medulloblastoma.
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